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Patients with acute respiratory
distress syndrome (ARDS) have a deficiency of surfac-
tant. Surfactant replacement improves physiologic func-





We conducted a prospective, multicenter,
double-blind, randomized, placebo-controlled trial involv-
ing 725 patients with sepsis-induced ARDS. Patients were
stratified according to the risk of death at base line (indi-
cated by their score on the Acute Physiologic and Chronic
Health Evaluation [APACHE III] index) and randomly as-
signed to receive either continuously administered syn-
thetic surfactant (13.5 mg of dipalmitoylphosphatidylcho-
line per milliliter; 364 patients) or placebo (0.45 percent




The demographic and physiologic charac-
teristics of the two treatment groups were similar at base








17 years in the sur-




18 years in the placebo group,









25, respectively. Hemodynamic meas-
ures, measures of oxygenation, duration of mechanical
ventilation, and length of stay in the intensive care unit
did not differ significantly in the two groups. Survival
at 30 days was 60 percent for both groups. Survival
was similar in the groups when analyzed according to
APACHE III score, cause of death, time of onset and
severity of ARDS, presence or absence of documented
sepsis, underlying disease, whether or not there was a
do-not-resuscitate order, and medical center. Increased
secretions were significantly more frequent in the surfac-
tant group; the rates of other complications were similar




The continuous administration of aero-
solized synthetic surfactant to patients with sepsis-
induced ARDS had no significant effect on 30-day sur-
vival, length of stay in the intensive care unit, duration of
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 described the acute respi-
ratory distress syndrome (ARDS) in 1967, they
suggested that the clinical and pathological findings in
patients with this condition were in part due to abnor-





both qualitative and quantitative abnormalities in lung





firmed that surfactant not only is decreased in quan-
tity but also is functionally abnormal in patients with
ARDS. These studies offer evidence that ARDS is a con-




Recent data suggest that mechanical ventilation may





the use of high tidal volumes, but not high pressures, re-
sults in lung injury. It seems reasonable to assume that if
surfactant replacement results in a more equitable distri-
bution of tidal volume among the alveoli, it might reduce
the damage caused by mechanical ventilation. It might
also help reinflate collapsed areas of the lung, improve
lung compliance, and reduce intrapulmonary shunting,
thus leading to reductions in morbidity and mortality.
On the basis of these observations and the similari-
ties between ARDS and the neonatal respiratory dis-
tress syndrome, surfactant-replacement therapy has been




 and phase 2 stud-




 Although their results
were encouraging, these studies were small and were
designed primarily to address issues of safety, rather
than efficacy.
We evaluated the efficacy of surfactant replacement
in a prospective, multicenter, randomized, double-blind,
placebo-controlled study of patients with sepsis-induced
ARDS. The primary objective was to test the hypothe-
sis that treatment with exogenous surfactant would re-
duce mortality at 30 days. Surfactant treatment was
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also evaluated for its effects on hemodynamic, ventila-
tory, and oxygenation-related variables; the duration of
mechanical ventilation, the length of stay in the inten-
sive care unit, and the duration of oxygen supplemen-








The study was conducted between March 1992 and September 1993
in the medical–surgical intensive care units of 63 hospitals in nine
countries. The study protocol was approved by each institutional re-
view board, and a signed consent form was obtained from each patient
before enrollment, if possible; otherwise, consent was obtained from
the patient’s next of kin or a legal representative. Patients were ran-
domly assigned to receive either aerosolized surfactant (13.5 mg of di-
palmitoylphosphatidylcholine [DPPC] per milliliter; Exosurf, Glaxo
Wellcome, Research Triangle Park, N.C.) or placebo (0.45 percent sa-
line) continuously for up to five days. Patients were stratified at ran-
domization according to their risk of death, as indicated by their scores





 Group assignment was balanced within and among all
centers and strata by means of an adaptive computerized randomiza-
tion program applied at an independent central facility. The study con-
sisted of a screening period during which the diagnosis of sepsis or sep-
sis syndrome and ARDS was established, a treatment period during
which the study drug was administered for up to 5 days, a post-treat-
ment period of 24 hours after the discontinuation of the drug, and a
follow-up period consisting of the 30 days after randomization. Two in-




Because the cause of ARDS may affect its outcome, we evaluated
only patients with ARDS caused by sepsis; ARDS caused by other con-
ditions was evaluated separately. ARDS was considered present if the
patient had diffuse infiltrates visible on the chest radiograph, a ratio













250), and no evidence




 For patients to be included, ARDS had
to have begun within 48 hours, the patients had to be receiving me-
chanical ventilation with a tidal volume of 150 ml or more, and ARDS
had to be associated with sepsis or sepsis syndrome (within 96 hours),





excluded if they were enrolled in another randomized study or if they
had left ventricular failure, chronic pulmonary disease requiring the
use of supplementary oxygen, acute renal failure or worsening chronic
renal failure, acute hepatic failure, disseminated intravascular coagu-
lation, suspected inhalation injury, infection with the human immuno-




 pneumonia, or a terminal ill-
ness with a life expectancy of less than three months. Renal or hepatic
failure and disseminated intravascular coagulation were defined ac-
cording to preset laboratory criteria.
 
Base-Line and Follow-up Assessments
 
The base-line evaluation consisted of a medical history taking and
physical examination; 12-lead electrocardiography; standard hemato-
logic and blood-chemistry measurements and urinalysis; chest radi-
ography; and blood cultures. During treatment, during the 24-hour
post-treatment period, and at the follow-up examinations we meas-
ured hemodynamic variables and arterial-blood gas values and ob-
tained ventilatory data. The number of days of mechanical ventilation,
the length of stay in the intensive care unit and in the hospital, and
the number of days of supplemental oxygen during the 30 days after
randomization were also recorded. Survival was evaluated after 30
days, and causes of death were determined. Information on adverse




In this study we used a synthetic surfactant, Exosurf (Glaxo




 This preparation is a mixture
of DPPC, cetyl alcohol, tyloxapol, and sodium chloride in a ratio of
13.5:1.5:1.0:5.8, respectively; the preparation contained 13.5 mg of
DPPC per milliliter after dilution with 0.45 percent saline.
After each patient underwent randomization, 240 ml of surfactant
or 0.45 percent saline was placed in an opaque canister (Tri-NEB 400;
Vortran Medical Technologies, Sacramento, Calif.) and administered
as an aerosol through a Visan-9 nebulizer (Vortran Medical Technol-
ogies). The study drug was aerosolized into the inspiratory limb of the
ventilator circuit during the expiratory phase and was delivered to the




 The weights of the canister









SD. The target sample size was
based on the number of deaths anticipated in the study population. A
sample in which there were 306 deaths among the patients would pro-
vide the study with 90 percent power to detect a 25 percent relative
improvement in survival with surfactant treatment. Assuming 50 per-
cent mortality in the placebo group, we calculated that 700 patients
should be enrolled. Two interim analyses were conducted, after 102
and 204 deaths had occurred. No further patients were enrolled after
the second interim analysis indicated it was futile to continue this
study of efficacy. The final sample size was 725 patients, 288 of whom
died. All patients randomly assigned to study groups were included in
analyses of efficacy and safety. Patients were assigned to low-, inter-
mediate-, and high-risk categories on the basis of their APACHE III
scores (0 to 45, 46 to 89, and 90 to 299, respectively). Survival at 30
days was assessed by means of a Cochran–Mantel–Haenszel test with





were performed in subgroups of patients defined by the following var-









 ratio, the medical center where the patient was enrolled, the
mortality rate in the placebo group at that medical center, the pres-
ence or absence of a positive blood culture at randomization, the pres-
ence or absence of a do-not-resuscitate order, the cause of ARDS (pneu-
monia vs. other conditions), method of mechanical ventilation, and
geographic area. Exploratory logistic-regression analyses were also
performed to assess the effects of age, ventilatory measures, and con-
comitant therapies on mortality at 30 days and the amount of drug
aerosolized (dose). Kaplan–Meier step-function plots were used to




 The degree of
improvement in continuous physiologic variables was compared in the
two groups by means of an analysis of the average area under the
curve. The incidence of adverse events and expected medical compli-
cations of ARDS was calculated, and the two groups were compared






The study population consisted of 725 patients (424





(range, 16 to 90); 361 patients (49.8 percent) received
placebo and 364 (50.2 percent) received surfactant.
The groups were similar at base line with respect to
age, sex, race, APACHE III score, mean arterial pres-













, the partial pressure of arterial car-




 (Table 1). In addition, the distri-
bution of underlying medical conditions and variables
indicating the medical history was similar in the two
groups. The primary diagnoses leading to admission to
the intensive care unit were medical conditions (i.e.,
not requiring surgery) for 75 percent of the placebo
group and 69 percent of the surfactant group. The
source of sepsis was similar in both groups (pulmonary,
39 percent; nonpulmonary, 61 percent), and pneumo-
nia was the most common condition precipitating sep-
sis (in 18 percent in the placebo group and 19 percent
in the surfactant group). Blood cultures were positive
before randomization for 28 percent of the patients in
the placebo group and 32 percent in the surfactant
group. Gram-positive organisms were isolated from
blood from 72 percent of the patients in the placebo
group and 68 percent of those in the surfactant group. 
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A total of 257 patients in the placebo group (71 per-
cent) and 268 in the surfactant group (74 percent) com-
pleted five days of aerosolized treatment. The reasons
for the early termination of treatment were similar in
the two groups and included death, extubation, and a
change to a method of assisted ventilation that was in-
compatible with the use of the nebulizer. Both groups
received similar volumes of the study preparations. The
surfactant group received an estimated 112 mg of aero-
solized DPPC per kilogram of body weight per day; this
amount is based on the mean weight of the canister be-
fore and after the drug was delivered. The response of
both groups to treatment was similar in terms of the al-









 (Fig. 1B). The characteristics of venti-
lation and the results of the analysis of the area under
the curve for other physiologic variables did not differ
significantly between the study groups.
In both groups, there was a 60 percent survival rate
30 days after randomization (Fig. 2). The primary caus-
es of death were respiratory disease and multiple-organ
failure (Table 2). Both treatment groups had similar
mortality rates in subgroups defined according to the
severity of ARDS at base line, APACHE III score, du-









status, and the number of patients enrolled at the med-
ical center. There were no significant differences in mor-
tality rates between the groups according to initial diag-
nosis, medical center, country, or method of mechanical
ventilation. The placebo and surfactant groups were
similar in terms of the mean number of days of mechan-


















1.1 days), the number of days of



















Serious adverse events occurred in 8 of the 725 pa-
tients and were associated with the administration of
the study preparations. These events included hypoten-
sion in three patients (two in the placebo group and one
in the surfactant group), barotrauma (one patient in
each group), worsening hypoxemia (one in the surfactant
group), respiratory arrest (one in the surfactant group),
and increased peak inspiratory pressure (one in the sur-
factant group). Most of these events were probably due
to unrecognized air trapping (intrinsic [“auto”] posi-
tive end-expiratory pressure), occlusion of the expira-
tory filter, or mucous plugging. Table 3 shows the fre-
quency of the ARDS-associated complications defined
in the protocol. Increased secretions were more fre-
quent in the patients given surfactant, but other com-






In this study, we determined the demographic charac-
teristics of a large group of patients with ARDS and eval-
uated the results of treatment with placebo or aerosol-
ized synthetic surfactant. We found that among patients
with sepsis-induced ARDS, aerosolized exogenous sur-
factant did not improve oxygenation, peak airway pres-
 




SD. APACHE denotes the








 the fraction of in-




 the partial pressure of arterial carbon
dioxide. Because of rounding, percentages may not total 100.
 
Table 1. Base-Line Demographic and Clini-
cal Characteristics of the 725 Patients, Ac-





















































Mean APACHE III score













































































































SD) Changes in Indexes of Oxygenation in the
Surfactant and Placebo Groups.
Panel A shows the decreases (indicated by negative numbers)
in the alveolar–arterial oxygen gradient during the administra-
tion of placebo or surfactant. There were no significant differ-
ences between the groups. Panel B shows the percent change








 from base line. The surfactant group
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sure, or overall survival at 30 days, nor did it reduce the
amount of time patients required mechanical ventilation,
the need for oxygen supplementation, or the length of
the stay in the intensive care unit or the hospital.
Previous studies suggested the potential efficacy of





every 12 hours or continuously for five days, aerosolized
surfactant was well tolerated and its use was associated





 More dramatic improvement was
seen when higher concentrations of aerosolized surfac-




 Our study differs
from these previous studies in several ways. We studied
725 patients, as compared with 51
 
11 and 4914; the pa-
tients we studied were enrolled within 48 hours after
the diagnosis of ARDS, instead of 72 hours; the ratio of
PaO2 to FiO2 was less than 250, rather than less than
299; and an updated delivery system and a liquid for-
mulation of surfactant were used. Despite these differ-
ences in the protocols, patients in our study and those
of Weg et al.11 and Reines et al.14 had similar base-line
characteristics, including age, FiO2, ratio of PaO2 to
FiO2, positive end-expiratory pressure, peak inspirato-
ry pressure, and duration of ARDS at study entry.
Thus, it is likely that the larger number of patients in
this study accounts for the differences in outcome. Oth-
er pilot studies8,12,13 are difficult to compare with ours
both because they were small and because they did not
provide detailed descriptions of the study groups.
There are several possible explanations for the lack
of effect of exogenous surfactant in the patients with
sepsis-induced ARDS in our study. First, although
ARDS is a state of surfactant deficiency, the mecha-
nisms involved are complex. ARDS associated with
sepsis is caused by an increase in endothelial and epi-
thelial permeability in the lung, with an associated in-
flammatory response.23 Surfactant replacement may
simply not be sufficient to affect the symptoms of ARDS.
Furthermore, many of our patients died from multiple-
organ failure, which was a sequela of sepsis and was un-
related to the initial pulmonary insult.
Another explanation could be our inability to deliver
enough aerosolized surfactant to the patients’ lungs.
Only 4.5 percent of radiolabeled surfactant reached the
lungs in studies using the same delivery system.24 Al-
though no direct data on the amount of surfactant de-
livered to the lungs were obtained in this study, we es-
timate that less than 5 mg of the dose of 112 mg of
aerosolized DPPC per kilogram per day was actually
delivered to the lungs. Although aerosolized surfactant
may be deposited in less severely injured areas,25 ad-
ministration by nebulizer has been shown to be superi-
or to tracheal instillation in some models.26 Recent data
on rabbits indicate that other factors, including the ven-
tilatory method27 and the level of positive end-expira-
tory pressure,28 may also influence the delivery of sur-
factant. Considering that no physiologic effect was seen
in our patients, an insufficient dose of surfactant is a
likely explanation for our results.
The synthetic surfactant preparation we used may
also have influenced the results. This preparation lacked
a protein component, a fact that may have affected its
onset of action and the susceptibility of the surfactant
to inhibition by serum proteins. However, this prepara-
tion is similar in efficacy to other surfactants that con-
tain protein and that are used in the treatment of neo-
natal respiratory distress syndrome.10 Furthermore, like
other surfactants,29 the surfactant we used has antiin-
flammatory effects, including the inhibition of the pro-
duction of tumor necrosis factor a,30 suppression of in-
Figure 2. Kaplan–Meier Curves Showing the Percentage of Pa-
tients Surviving in the Placebo Group (Solid Line) and Surfac-





















0 105 15 20 25 30
Days after Randomization
*Includes initial pneumonia that did not resolve, nosocomial
pneumonia, and respiratory failure.








Respiratory disease* 46 (32) 44 (30)
Multiple-organ failure 37 (26) 38 (26)
Sepsis or septic shock 27 (19) 38 (26)
Cardiac arrest 13 (9) 15 (10)
Other 20 (14) 10 (7)
*Only complications with an incidence greater than 1 percent
are listed.
†P0.05 for the comparison with the placebo group. 
‡Includes pneumothorax, pneumomediastinum, pneumoperi-
cardium, and pneumatocele.








Increased secretions 11 25†
Hypotension 36 36
Tachycardia 28 28
Other arrhythmias 18 16





Worsened mental status 9 9
Hepatic failure 7 4
Gastrointestinal bleeding 4 4
Accidental extubation 3 2
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terleukin-1 and interleukin-2,31 and inhibition of the
endotoxin-stimulated secretion of cytokines by alveolar
macrophages.32 
Since the description of ARDS in 1967,1 the rate of
survival among patients with this syndrome has been
about 20 to 40 percent. However, Suchyta et al.33 re-
cently reported increased survival in a subgroup of pa-
tients with ARDS who met criteria for extracorporeal
membrane oxygenation. In analysis of data from a mul-
ticenter registry, Sloane et al.34 reported a survival rate
of 46 percent. Mitchell et al.35 reported an improve-
ment in survival, to 62 percent, at a single institution
from 1983 to 1992. Milberg et al.36 reported survival
rates that increased from 33 percent in 1990 to 60 per-
cent in 1993, with most of the improvement accounted
for by patients with sepsis-induced ARDS. We found a
survival rate of 60 percent for sepsis-induced ARDS,
similar to the rates in these recent reports.35,36 
We are indebted to the study coordinators, clinical research associ-
ates, and pharmacists who participated in this trial and to Janis Kay
Marsh for assistance in the preparation of the manuscript.
APPENDIX
The members of the Exosurf Acute Respiratory Distress Syndrome
Sepsis Study Group were as follows: R.S. Tharratt (Sacramento, Cal-
if.); E. Caldwell (Portland, Me.); R. Balk (Chicago); H. Paz (Philadel-
phia); N. MacIntyre (Durham, N.C.); S.M. Fakhry (Chapel Hill,
N.C.); L. Napolitano (Worcester, Mass.); J. Warren (Pittsburgh);
J. Messick and R. Corbin (Charlotte, N.C.); S. Koerner (Los Ange-
les); H. Silverman and J. Britten (Baltimore); P. Lanken (Philadel-
phia); D. Schuster (St. Louis); J. Hurst (Tampa, Fla.); J. Williams
(Orange, Calif.); B. DeBoisblanc (New Orleans); L. Rotello (Syra-
cuse, N.Y.); S. Peters (Rochester, Minn.); D. Scholten (Grand Rapids,
Mich.); B. Soifer (Portland, Oreg.); K. Davis (Cincinnati); J. Shah,
E. de Maria, and C. Sessler (Richmond, Va.); R. Treat (Birmingham,
Ala.); D. Dries (Maywood, Ill.); S. Jenkinson (San Antonio, Tex.);
M. Tweeddale (Vancouver, B.C.); W.D.N. Chin, R. Johnston, and
D. Stollery (Edmonton, Alta.); P. Boiteau and S. Viner (Calgary, Al-
ta.); D. Johnson (Saskatoon, Sask.); P. Gray (Winnipeg, Man.);
G. Darling, D. Jones, R. Grossman, R. Byrick, and W. DeMajo (To-
ronto); R. Hodder (Ottawa, Ont.); J. Malo, Y. Berthiaume, and
P.  Goldberg (Montreal); A. MacNeil (Halifax, N.S.); H.A. Bruining
(Rotterdam, the Netherlands); F. Brunet and C. Gibert (Paris);
W. Tullett (Glasgow, United Kingdom); P. Damas (Liege, Belgium);
R. Hopkinson (Birmingham, United Kingdom); G. Lavery (Belfast,
United Kingdom); P. Lehmkuhl (Hannover, Germany); W. Schaffart-
zik (Berlin, Germany); R. Wenstone (Liverpool, United Kingdom);
T. Evans and D. Bihari (London); L. Heslet (Copenhagen, Denmark);
and R. Kishen (Salford, United Kingdom).
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